The company now expects 2025 non-GAAP EPS of $5.35-$5.39, compared with the $5.25 consensus and its previous guidance of $5.15-$5.30. Q4 non-GAAP EPS guidance is $1.27-$1.31 vs. the average analyst ...
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback